Navigation Links
Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinson's Disease Research Models
Date:10/1/2009

NEW YORK and ST. LOUIS, Oct. 1 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) and The Michael J. Fox Foundation (MJFF) today announced a collaboration that is expected to develop more accurate preclinical research models of Parkinson's disease, a neurodegenerative disorder of unknown cause that affects nearly five million individuals worldwide(i). Under a research grant from MJFF, Sigma Advanced Genetic Engineering (SAGE(TM)) Labs - an initiative of Sigma-Aldrich's Research Biotech business unit - will use novel CompoZr(TM) zinc finger nuclease (ZFN) technology in an effort to create superior preclinical research models critically needed for the development of transformative treatments for Parkinson's disease. The models, which are expected to take as little as one year to develop, will be made broadly accessible to scientists throughout the Parkinson's research community in order to speed basic research and drug development efforts field-wide.

Though current mammalian models adequately recapitulate some outward symptoms of Parkinson's disease, no existing model has been able to accurately mimic the onset and progression of the underlying disease processes that characterize that disease in humans. Research already conducted into the genetic causes of Parkinson's disease has identified a number of genes but indicates a strong connection to mutations in five particular genes: LRRK2, alpha-synuclein, DJ-1, Parkin and PINK1. MJFF funding will allow Sigma-Aldrich's efforts to create five novel rat models with each of these genes knocked out.

Adopting a new approach to developing more effective and targeted research models, SAGE Labs will use the CompoZr ZFN technology in its efforts to design 'knockout' rat models in which the genes known to be directly implicated in Parkinson's disease are omitted. This research is expecte
'/>"/>

SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
2. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
3. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
4. Oxygen Biotherapeutics, Inc. Receives Phase II Trial Approval in Israel
5. Childrens Hospital Receives Six-Year Federal Contract to Study Antibiotic Use in Children With Urinary Tract Infections
6. ISTA Pharmaceuticals Bepreve(TM) Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
7. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
8. Cytopias CYT387 Receives FDA Clearance to Start US Clinical Trials
9. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
10. Families of Spinal Muscular Atrophy Receives FDA Orphan Drug Designation For Quinazoline495 For The Treatment of Spinal Muscular Atrophy
11. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... 10 Eli Lilly and Company (NYSE: LLY ... the Second Circuit has agreed with Lilly,s position that a ... payor suit, in which unions and insurers who act as ... court also agreed with Lilly that plaintiffs, overpricing claims should ...
... (NYSE Amex: PTN ) announced that it will ... Conference / 12th Annual Healthcare Conference on Tuesday, September 14, ... September 12-15 at the New York Palace Hotel in New ... Chief Executive Officer of Palatin Technologies, will provide an update ...
Cached Medicine Technology:U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly 2
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... created a new technology for modifying human cells ... body and selectively target cancer and other sites ... monitor and modify human physiology is a promising ... technology enabled bioengineers to build such devices that ... a customized fashion. , "The project addressed a ...
(Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... effects, is serious enough to be considered a health risk. ... or fewer hours were more likelier to have a heart ... too much sleep isn't good, either, as researchers found that ... also increased their heart disease risk. ,The study, conducted ...
... rate for potential medical problems, according to earlier studies, is ... for babies in hospitals are even higher. However, a new ... Agency for Healthcare Research and Quality (AHRQ) may help prevent ... is aimed at pediatricians and parents, and includes a fact ...
... the United States have found that the practice of ... past 14 years. However, they suggested that patients with ... Pylori(H.Pylori) infection rather than receiving treatment for the infection ... appropriate option// than empiric treatment in patients with peptic ...
... wasting condition which is a serious problem in people with ... bowel, liver, lungs and heart. A recent study has found ... in fruit flies, where it is involved in muscle development, ... ,Researchers have been studying the function of the twist ...
... has identified independent factors that are associated with ... the study, information was gathered from the 1999 ... evaluate common factors in 1,810 diabetic Americans.// ... were found to have more primary care and ...
... The myth that eating nuts makes one fat has ... mono and polyunsaturated fats are good while simple carbohydrates ... low-density lipoprotein cholesterol, the good kind. Monounsaturated fat does ... in heart disease. ,Preliminary evidence shows that even ...
Cached Medicine News:
Designed to meet the demands of today's laboratories for RO water....
... L/day of Type III Laboratory-grade Water, RiOs ... up to 8000 L/day of Type III ... Complete Purification and Control Unit, RiOs systems ... providing total control of all parameters within ...
... RiOs systems produce Type III, laboratory-grade ... Systems are fed directly with potable tap ... a compact system design that is easy ... over the water produced at a low ...
... Model U410 is an upright freezer ... our Innova line, but using conventional ... a cost-effective alternative. Similar in size ... 240 2" boxes. Includes five compartments ...
Medicine Products: